JFG
NMRA icon

Jefferies Financial Group’s Neumora Therapeutics NMRA Stock Holding History

Jefferies Financial Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,100
Closed -$160K – 1876
2024
Q4 		$160K Buy
+15,100
New +$181K ﹤0.01% 1407

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jefferies Financial Group's NMRA Position: Q2 2026 in Review

Jefferies Financial Group sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 33,044 shares — an estimated $64.4K sold.

Jefferies Financial Group first reported a position in NMRA in Q2 2024 and held it in 5 quarters. The position peaked at $319K in Q2 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Jefferies Financial Group reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 33,044 Neumora Therapeutics shares in Q2 2026, an estimated $64.4K.
  • Jefferies Financial Group first reported a position in Neumora Therapeutics in Q2 2024 and held it in 5 quarters.
  • Jefferies Financial Group's Neumora Therapeutics position peaked at $319K in Q2 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.